Overview

Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma

Status:
Completed
Trial end date:
2018-08-02
Target enrollment:
Participant gender:
Summary
The aim is to study the effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with severe, refractory eosinophilic asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Atopix Therapeutics, Ltd.
Chiesi Farmaceutici S.p.A.
Collaborator:
Atopix Therapeutics, Ltd.
Treatments:
Indoleacetic Acids